Australiahealth

Amplia Therapeutics (ASX:ATX) has partnered with the Australia New Zealand Gynaecological Oncology Group to launch a new clinical trial targeting ovarian cancer.

Ramsay Santé booked a 3.1% revenue rise to €4bn in its 9M results, driven by strong Nordic performance and French demand.

PYC Therapeutics (ASX:PYC) announced the dosing of the first patient in the Phase 1b multiple ascending dose study of PYC-003.

Neuren Pharmaceuticals (ASX:NEU) reported net sales of its flagship Rett syndrome treatment, DAYBUE (trofinetide) in Q1.

Arovella Therapeutics (ASX:ALA) appointed Dr Nicole Van Der Weerden as acting CEO, effective immediately.

Anteris Technologies (ASX:AVR) treats first US patients in PARADIGM trial, marking a major milestone for its DurAVR heart valve.

Health technology firm Beamtree (ASX:BMT) announced a pivotal $2 million contract with Saudi Arabia’s Fakeeh Care Group.

Entropy Neurodynamics (ASX:ENP) strengthened its "gut-brain" portfolio with a new US patent filing for treatment-resistant IBS.

Nova Eye Medical (ASX:EYE) upgraded FY26 sales guidance to US$22–23 million following record-breaking monthly sales in the USA.

Sigma Healthcare (ASX:SIG), via Chemist Warrehouse, secured a majority stake in the London-based Greenlight Healthcare chain.